Education
About Us
Working with TipRanks
Follow Us
Enovis (ENOV)
NYSE:ENOV
ENOV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$35.14 - $62.79
Previous CloseN/A
Volume391.51K
Average Volume (3M)908.75K
Market Cap
$2.15B
Enterprise Value$3.81B
Total Cash (Recent Filing)$42.78M
Total Debt (Recent Filing)$85.00M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
May 01, 2025EPS Estimate
0.74Last Dividend Ex-Date
Apr 05, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-14.81
Shares Outstanding56,963,440
10 Day Avg. Volume762,764
30 Day Avg. Volume908,755
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.06
Price to Cash Flow (P/CF)6.30
P/FCF Ratio12.50
Enterprise Value/Market Cap1.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.23
Enterprise Value/Ebitda-7.48
Forecast
1Y Price Target
$62.71Price Target Upside64.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Enovis News
PremiumCompany Announcements
Enovis CEO Matthew Trerotola Announces Retirement Plan
PremiumCompany Announcements
Enovis Corporation Reports Strong Growth Amid Challenges
PremiumCompany Announcements
Enovis Corporation Faces Financial Strain Amid U.S.-China Tariff Uncertainty
PremiumCompany Announcements
Enovis Corporation Reports Strong Sales Growth Amid Challenges---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEnovis reported a strong beat across the P&L as it delivered DD growth in recon with the Lima integration continuing to track above ENOV's expectations.
Market PositionEnovis has grown its shoulder market share to become what it believes is the #3 player in the US, with innovative products and recent launches.
ValuationShares are at an attractive risk/reward for a company with a clear pathway to durable margin expansion and compounding profitability.
Bears Say
LeadershipENOV has started a search process for a CEO replacement.
Revenue EstimateUpdating the model post earnings resulted in a slight reduction in the 2025 revenue estimate.
UncertaintySentiment is being weighed by multiple small factors creating uncertainty around the durability of the P&L.
---
Ownership Overview
1.38% Insiders
39.46% Mutual Funds
0.80% Other Institutional Investors
32.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENOV FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest stock price was $35.14 and its highest was $62.79 in the past 12 months.
What is Enovis’s market cap?
Enovis’s market cap is $2.15B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is May 01, 2025 which is in 29 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Feb 26, 2025. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.916 by $0.064.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis pays a Notavailable dividend of $16.666 which represents an annual dividend yield of N/A. See more information on Enovis dividends here
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.74.
How many shares outstanding does Enovis have?
Enovis has 56,963,440 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.98 in its last earnings report, beating expectations of $0.916. Following the earnings report the stock price went down -4.988%.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in ENOV
---
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.71 (64.12% Upside)
$62.71 (64.12% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 170.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.2%
Last 30 Days ▼ 14.5%
Last 30 Days ▼ 14.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.53%
12-Months-Change
Fundamentals
Return on Equity
-27.69%
Trailing 12-Months
Asset Growth
4.64%
Trailing 12-Months
Company Description
Enovis
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
---
ENOV Company Deck
---
ENOV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant revenue growth and successful integration of the Lima acquisition, with strong new product launches and improved EBITDA margins. However, challenges include a substantial goodwill impairment, increased interest expenses, and potential tariff impacts. The positive aspects, particularly the strong growth and synergy realization, outweigh the negatives.Read More>---
ENOV Stock 12 Month Forecast
Average Price Target
$62.71
▲(64.12% Upside)
Technical Analysis
Best Analysts Covering ENOV
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-12.81%
reiterated a buy rating 5 months ago
Copying Jeff Johnson's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -12.81% per trade.
---